TheraRadar
← Back
Data updated: Nov 8, 2026

ETON

Specialty
Pharmaceuticals

ETON is a specialty pharmaceutical company with 8 FDA-approved products.

1997
Since
8
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
6 Small Molecules

ETON's Recent FDA Approvals

ETON secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

DESMODA NDA
2026-02-25
desmopressin acetate
1 INDICATIONS AND USAGE DESMODA is indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. Limitations of Use • DESMODA is not indicated for the treatment of nephrogenic diabetes insipidus. DESMODA is a vasopressin analog indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. Limitations of Use • DESMODA is not indicated for the treatment of nephrogenic diabetes insipidus.
KHINDIVI NDA
2025-05-28
hydrocortisone
Adrenocortical Insufficiency

ETON's Therapeutic Areas

Disease areas where ETON has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

ETON Pipeline Snapshot

Active clinical trials for ETON across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • IMPAVIDO leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling